We are glad to invite you to meet our staff at ESHG 2016 (stand #250) in Barcelona, May 21-23. We will be presenting several new tests and services at the exhibition.
To benefit more from our thorough results reports, we’d like to make an excellent offer for our current and new customers. Our diagnostic package service that includes detailed medical interpretation is available with the price of genotyping service for all NGS panels ordered from the beginning of May to the end of June. So, don’t miss to call on our booth to learn more about the new gene panels and services, and let us know how we can improve.
Asper Biotech is celebrating its 15th year in genetic testing. Since founding in 1999 it has seen great development in understanding the changes in human genes from sophisticated science projects to the everyday use of genetic data. By celebrating its 15th anniversary and honoring new technologies Asper Biotech is offering 15% discount from all Next Generation Sequencing tests during its birthday month from 17th of March to 17th of April. Just contact info[at]asperbio.com for more information.
Asper Biotech is offering whole exome sequencing at introductory price of 890 Euros providing average coverage of 50x per exome.
As the summer is approaching it is now a good time to collect samples for sequencing with excellent quality and low-cost. The call for sample shipment starts today and lasts till the 31st of August.
- Price 890 Euros per sample
- 50x coverage
- Annotated VCF file
- Target region size 37 Mb
- Number of target exons 201 121
- Final day for the shipment 31st of August
- TAT 13 weeks
Just place the samples in the envelope, include the filled form and send to
Ph: +372 7307 295
PS. Please note that although diagnostic package is also included to the form the stated price is for genotyping service only.
Genetic testing company Asper Biotech has been acquired by Asper Biogene LLC and hereafter will be operating under the name of Asper Biogene. The deal was concluded in July 2017 to enhance the testing services and expand into new markets. The company is maintaining its focus on diagnostics for rare and common hereditary diseases.
Our testing menu has become one of the most comprehensive in the clinical diagnostics field. Starting with tests for eye diseases, we have broadened the testing scope, which now encompasses to neurological, cardiological, oncological, hematological etc. areas. Besides our best-known portfolio – Asper Ophthalmics seven new testing portfolios have been launched. As our aim is to provide flexible and customer-friendly services, our clients are always encouraged to ask for customized tests and testing solutions.
Our laboratory is an authorized medical laboratory, CLIA (#99D2046227), ISO 15189:2012, and ISO 9001:2015 certified. We are participating in the European Molecular Genetics Quality Network (EMQN) quality assessment schemes in order to deliver genetic services at the highest level of quality standards.
Our clients, including leading university hospitals, private clinics, commercial laboratories and research organisations are from more than 40 countries. Development and elaboration of new tests are continuous processes in our daily practice to meet the customers’ needs and provide testing services to more patients and healthcare providers. We are also offering custom-test development with complete workflow and full customer support.
Besides providing genetic diagnostic services, we are an appreciated scientific partner for many international R&D projects due to our innovation-driven approach and long-lasting experience. We have had successful collaboration with different funding agencies supporting R&D activities, which have led to technological improvements and moreover to state-of-the-art genetic tests. Our expertise is widely recognized by participation in numerous European-wide research projects where we have been incorporated as an essential partner.
About Asper Biotech
Asper Biotech was established in 1999 as a spin-off of the University of Tartu. Since then Asper Biotech quickly became a leading Estonian biotechnology exporter due to its extensive services and the quality of the results.
Asper Ophthalmics is a comprehensive collection of genetic tests targeted at the diagnostics of a wide variety of hereditary ocular disorders, including retinal disorders, corneal dystrophies, and age related ophthalmic conditions.
Our genetic tests assist clinicians in confirming diagnoses and informing patients about their risks for inherited eye diseases.